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Surface displaying of swine IgG1 
Fc enhances baculovirus-vectored vaccine 
efficacy by facilitating viral complement escape 
and mammalian cell transduction
Zehui Liu†, Yangkun Liu†, Yuanyuan Zhang, Yajuan Yang, Jingjing Ren, Xiaoying Zhang* and Enqi Du*
Abstract 
Baculovirus-mediated gene transfer has been developed as a vaccine design strategy against a number of diseases 
without apparent viral replication. However, it has been hampered by complement-dependent inactivation, thus hin-
dering the in vivo application of baculovirus. A variety of approaches have been exploited to bypass the complement 
system in the serum. In this study, we constructed and screened a series of baculovirus vectors displaying comple-
ment interfering factors, of which a baculovirus vector displaying swine IgG1 Fc (pFc) showed the highest comple-
ment antagonism (75.6%). Flow cytometry analysis of transduced cells demonstrated that the baculovirus display of 
pFc had a significant increase in transduction efficiency and transgene expression of reporter genes. On this basis, a 
VSV-G-pseudotyped with swine IgG1 Fc surface displayed baculovirus vector was developed to express the classical 
swine fever virus (CSFV) E2 gene. The translational enhancers Syn21 and P10UTR were incorporated to improve the 
antigen expression. The E2 gene was efficiently expressed in both insect and mammalian cells. Pigs immunized with 
this recombinant baculovirus developed high levels of E2-specific antibody, CSFV-specific neutralizing antibody and 
IFN-γ-secreting cellular immune responses. These results demonstrate that the strategy of surface-displaying swine 
IgG1 Fc has a great potential to improve the efficiency of baculovirus-vectored vaccine for CSFV and other swine 
pathogens.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
The baculovirus-based protein expression system has 
been used extensively to produce a variety of heteroge-
nous proteins in insect cells. Recombinant baculoviruses 
carrying mammalian cell active expression cassettes, 
BacMam viruses, have been developed as a vaccine strat-
egy against diseases in several animal models. Intramus-
cular, intraperitoneal or intranasal vaccination with these 
recombinant baculoviruses is shown to elicit humoral 
and cellular immune responses against various antigens 
[1, 2]. As a gene delivery vector, baculovirus offers several 
advantages over other viral vectors, including a strong 
biosafety profile [3, 4], a high capacity for insertion of 
heterologous DNA, and ease of production. In addi-
tion, baculovirus can be used as an adjuvant to stimulate 
the innate immune system by regulating toll-like recep-
tor 9 (TLR9) and RIG-I-like receptor (RLR) pathways 
[5]. Therefore, baculovirus is an effective tool for gene 
delivery.
Baculovirus infects insect cells in nature. The glycopro-
tein gp64 mediates virus attachment to the cell surface 
and internalization [6], which comprises an N-terminal 
signal peptide (SP) and a mature domain that includes 
the transmembrane domain (TM) and cytoplasmic 
domain (CTD). After anchoring in insect cells, the gp64 
SP directs its transport to the plasma membrane, where 
gp64 is exhibited on the surface of infected cells as 
homotrimers. The gp64 CTD interacts with the budding 
nucleocapsids and directs the incorporation of gp64 into 
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the virion [7]. Thus, foreign proteins coupled to gp64 will 
be routed efficiently to the cell membrane to be displayed 
on the surface of infected cells and on baculovirus parti-
cles. Recombinant baculoviruses made with this surface 
display technique have been used in a variety of applica-
tions, including functional studies of glycoproteins, drug 
screening and development of vaccine candidates [8, 9].
Although baculovirus does not suffer from pre-existing 
antibodies in vertebrates, baculovirus-based gene deliv-
ery faces two bottlenecks: complement-dependent inac-
tivation and low transduction efficacy targeting immune 
cells, such as dendritic cells, macrophages, B cells, and 
T cells. This has thus affected, to a great extent, the effi-
cacy of baculovirus-vectored vaccines [10]. A number of 
approaches have been applied to bypass the complement 
using chemical compounds or complement receptors, 
and surface display of complement inactivators, such as 
soluble complement receptor type 1 (sCR1), decay accel-
eration factor (DAF), membrane cofactor protein (MCP), 
Smallpox inhibitor of complement enzymes (SPICE) and 
ornithodoros moubata complement inhibitor (OmCI) 
[11]. A pseudotyped baculovirus replacing gp64 with 
vesicular stomatitis virus G (VSV-G) protein has shown 
improved efficiency in transducing various mammalian 
cells and antagonism against complement-mediated inac-
tivation [3].
Classical swine fever virus (CSFV) is a causative agent 
of CSF, a highly contagious Class A infectious disease 
being classified by the World Organization for Animal 
Health (OIE), leading to great economic losses in the pig 
industry [12]. The viral E2 glycoprotein is responsible for 
eliciting neutralizing antibodies in immunized animals 
and protecting them from lethal dose challenge. This pro-
tein also plays multiple roles in the viral life cycle, and 
mediating viral entry into host cells [13].
At present, the most extensively used CSFV vaccine 
is a lapinized attenuated vaccine based on the C-strain. 
Although it can confer complete protection against CSF, 
this vaccine does not allow differentiating infection in 
vaccinated animals (DIVA). Other vaccination strategies, 
such as avirulent and low-pathogenic viral vectored vac-
cines expressing E2 protein [14–16], still remain biosecu-
rity concerns.
In this study, we aimed to further improve baculovirus-
vectored vaccine efficacy. To explore the effects of com-
plement interfering factor OmCI, SPICE, DAF and pFc 
displayed on the baculoviral envelope for baculovirus-
mediated gene delivery, we constructed four recombi-
nant baculoviruses displaying OmCI, SPICE, DAF and 
pFc, respectively. We hypothesized that by displaying 
these elements, the in vitro complement antagonism and 
transgenic expression of these four recombinant bacu-
loviruses would promote as vaccine delivery vectors. 
The modified recombinant BacMam carrying CSFV E2 
expression cassette under the CMV promoter was tested 
as a novel CSFV vaccine in generating effective immunity 
in pigs.
Materials and methods
Virus, plasmids, and cells
The CSFV Shimen and CSFV C strains vaccine was pur-
chased from Jilin Zhengye Biological Products Co., Ltd, 
Jilin, China. The pFc, SPICE, DAF, OmCI and E2 genes 
were synthesized by GENEWIZ (Suzhou, China). E. coli 
SW106 (with multigene baculovirus expression vector 
AmMultiBac) was obtained from Professor Yao Lun-
guang of Nanyang Normal University, China. Plasmid 
pFBDM-VSV-ED-CMV-DsRed (containing the CMV 
promoter and VSVG-ED), swine intestinal epithelial 
cells (IEC), porcine kidney cells (PK-15) and Sf-9 insect 
cells were also maintained in our lab. The IEC and PK-15 
cells were cultured in Dulbecco modified Eagle medium 
(DMEM, HyClone, China) supplemented with 10% heat-
inactivated fetal bovine serum (FBS, Gibco, CA, USA), 
100  units/mL penicillin and 100  μg/mL streptomycin 
(Invitrogen), and incubated at 37  °C in a humidified 5% 
 CO2 atmosphere.
Construction of baculovirus vectors
Six plasmids including pFBDM-VSVG-ED-pFc-
CMV-DsRed, pFBDM-VSVG-ED-SPICE-CMV-DsRed, 
pFBDM-VSVG-ED-DAF-CMV-DsRed, pFBDM-VSVG-
ED-OmCI-CMV-DsRed, pFBDM-VSVG-ED-CMV-DsRed 
and pFBDM-gp64-CMV-DsRed, were constructed by 
standard methods. A recombinant baculovirus vector 
vaccine, pFBDM-VSVG-ED-CMV-E2, was constructed 
to express CSFV E2 gene derived from CSFV strain Shi-
men (Accession AY775178) under the control of CMV 
promoter, and pFBDM-VSVG-ED-pFc-CMV-S/P-E2 
plasmid was constructed by introducing translational 
enhancers Syn21 and P10UTR [17], into the above vec-
tor (Figure 1). The plasmids were transformed into E.coli 
SW106 competent cells, and recombinant Bacmid (rBac) 
DNA, including rBac-VSVG-ED-pFc, rBac-VSVG-ED-
SPICE, rBac-VSVG-ED-DAF, rBac-VSVG-ED-OmCI, 
rBac-VSVG-ED, rBac-gp64, rBac-VSVG-ED-CMV-
E2, and rBac-VSVG-ED-CMV-S/P-E2, were amplified 
by PCR amplification using gene-specific and M13R 
primers.
Generation and titration of recombinant baculovirus
Sf-9 insect cells were cultured at 27  °C in Sf-900II SFM 
medium containing 10% FBS (Gibco, CA, USA) and 1% 
antibiotics (100 U/mL penicillin and 100 μg/mL strepto-
mycin). The cells were transfected with each of the above 
recombinant Bacmid DNA, and the supernatant were 
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collected at 120 h after cultivation. The viruses were pas-
saged in Sf-9 cells to obtain high titer viral stocks. The 
culture supernatants from infected cells were collected 
once 90% of the cells had been infected. The recombinant 
baculovirus genome was extracted and then checked 
for the presence of the insert by PCR using gene-
specific and baculovirus polyhedron-specific primer 
pairs. The recombinant baculoviruses were named 
BV-VSVG-ED-pFc, BV-VSVG-ED-SPICE, BV-VSVG-
ED-DAF, BV-VSVG-ED-OmCI, BV-VSVG-ED, BV-gp64, 
BV-VSVG-ED-CMV-E2 and BV-VSVG-ED-pFc-CMV-
S/P-E2, respectively. The titer of the baculovirus stocks 
was measured by end-point dilution assay. Briefly, Sf-9 
cells were plated in 96-well plates, and tenfold serial 
dilutions of the virus stocks were added to the cells. 
Viruses and cells were allowed to interact for 1 h before 
the viruses were removed, and the cells were incubated 
for 8 days and examined for GFP expression. Wells that 
appeared green fluorescence  were deemed to be bacu-
lovirus-positive, otherwise deemed to be baculovirus-
negative. Subsequently, the titer for every virus stock was 
calculated according to the Reed-Muench method.
Western blot analysis of purified recombinant 
baculoviruses
The virus supernatant was purified by ultracentrifuga-
tion as described before [1]. Briefly, cell debris was first 
removed by centrifugation for 10  min at 2000  rpm. 
Infected cell supernatant was then layered over 27% 
sucrose and centrifuged at 24  000  rpm for 75  min in 
SW28 tubes. The virus pellet was resuspended in phos-
phate-buffered saline (PBS, pH 7.5) and centrifuged 
in SW28 tubes at 27  000  rpm for 150  min. The final 
pellet was resuspended in PBS. The incorporation of 
 His6-tagged pFc, SPICE, DAF, and OmCI into baculo-
viruses was probed using mouse anti-His6 monoclonal 
Figure 1 Identification of recombinant baculoviruses displaying complement interfering factors. A Schematic diagram of donor vectors 
of recombinant baculoviruses displaying complement interfering factors on the surface. CMV: human cytomegalovirus (CMV) immediate early 
enhancer and promoter, ph: AcMNPV polyhedrin promoter, p10: AcMNPV p10 promoter, gp64 SP: Autographa californica nuclear polyhedrosis 
virus (AcMNPV) gp64 signal sequence, MCS: multiple cloning sites, gp64 TM: AcMNPV gp64 transmembrane domain, gp64 CTD: AcMNPV gp64 
cytoplasmic domain, VSVG TM: vesicular stomatitis virus G protein (VSV-G) transmembrane domain, VSVG CTD: VSV-G cytoplasmic domain. B Confo-
cal microscopy analysis of  His6-tagged pFc, SPICE, DAF and OmCI proteins anchoring on the plasma membrane of Sf-9 cells. Protein localization was 
visualized in cell membrane using a confocal microscope by the primary antibody (anti-His6 monoclonal antibodies) and the secondary antibody 
(FITC-conjugated goat anti-mouse IgG). C Western blot analysis of  His6-tagged pFc (27 kDa), SPICE (26 kDa), DAF (36 kDa) and OmCI (18 kDa) in 
infected Sf-9 cells.
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antibody (Boster, Wuhan, China). The Sf-9 cells infected 
with recombinant BV-VSVG-ED-CMV-E2 or BV-VSVG-
ED-pFc-CMV-S/P-E2 baculovirus vaccine were analyzed 
by mouse anti-His6 monoclonal antibody or rabbit anti-
CSFV polyclonal antibody, followed by confirmation of 
the expression of pFc and E2.
Indirect fluorescent assay (IFA)
The IEC cells were collected at 48  h post-transduction, 
fixed with 4% paraformaldehyde for 20 min at room tem-
perature, and then exposed to rabbit anti-CSFV poly-
clonal antibody for 1 h at 37 °C. After three washes with 
PBS, the cells were incubated with Alexa 594-conjugated 
goat anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA) for 
1 h at 37 °C. Fluorescence images were collected using an 
inverted fluorescence microscope.
Confocal microscopy
The Sf-9 cells were cultured on sterile cover slips and 
infected at a multiplicity of infection (MOI) of 10. Two 
days after infection, the cells were fixed by methanol/
acetone (1:1) for 5 min at −20 °C, rinsed with PBS, and 
blocked with 5% skimmed milk for 30 min at 37 °C. The 
cells were then sequentially incubated with anti-His6 
mouse monoclonal antibody and FITC-conjugated goat 
anti-mouse IgG antibody (Boster, Wuhan, China) for 1 h 
at 37  °C, and washed for three times with PBS. Protein 
localization was visualized using a confocal microscope 
(LSM 510, Zeiss, Thornwood, NY, USA).
Complement antagonism of recombinant baculoviruses
One of the major challenges of baculoviruses as gene 
transfer vectors is inactivation by serum complement. We 
therefore tested the survival rate of recombinant baculovi-
ruses in the presence of serum. Briefly, healthy pig serum 
and mice serum were divided into two parts: one part 
was heat-inactivated at 56 °C for 30 min, another was left 
untreated. Recombinant baculoviruses were incubated 
with inactivated serum and untreated serum, respectively. 
After 60 min incubation at 37 °C, these recombinant bacu-
loviruses were subjected to titration by end-point dilution 
assay. The survival rates of baculoviruses were denoted 
as the percentage of vector survival in the indicated sera 
compared to the corresponding heat-treated sera [18].
Flow cytometry analysis
The IEC cells were transduced with BV-VSVG-ED-pFc 
or BV-VSVG-ED at a MOI of 100, and subjected to flow 
cytometry (FACSCalibur, BD Biosciences, Franklin Lakes, 
New Jersey) analysis 1  day after transduction. The per-
centage of cells emitting fluorescence (% dsRed +  cells) 
and mean FI of each sample were measured three times 
by counting 10 000 cells in each measurement.
Evaluation of recombinant baculovirus vaccines
Complement antagonism of BV-VSVG-ED-CMV-E2 
and BV-VSVG-ED-pFc-CMV-E2 was measured as men-
tioned above. Transduction efficiency of swine cells 
with recombinant baculovirus vaccines was also a criti-
cal checkpoint. A third passage (P3) of baculoviruses 
(BV-VSVG-ED-CMV-E2 and BV-VSVG-ED-pFc-CMV-
S/P-E2) was transduced with swine IEC using an MOI of 
100 for 12 h. The media containing the virus was replaced 
by fresh DMEM, and the cells were incubated for an 
additional 48  h before being fixed for IFA analysis as 
described above.
Pig immunization and immune response detection
Four week old pigs (CSFV antigen and antibody nega-
tive, provided by China Institute of Veterinary Drug 
Control) were randomly divided into 4 groups (5 pigs 
per group). The pigs were intramuscularly immunized 
with BV-VSVG-ED-CMV-E2 and BV-VSVG-ED-pFc-
CMV-S/P-E2 baculoviruses  (109 PFU), CSFV commer-
cial vaccine C-strain (vaccinated control, 2 mL), and PBS 
(unvaccinated control), respectively, boosted once at 
14 days. The CSFV-specific antibodies were tested in sera 
collected at 0, 7, 14, 21 and 28 days post-infection (dpi) 
using commercial ELISA kit (Keqian, Wuhan, China), 
and IFN-γ was assayed in sera collected at 0, 14 and 28 
dpi using a commercial ELISA kit (4A Biotech, Beijing, 
China). All animal procedures were approved and super-
vised by the Animal Care Commission of the College of 
Veterinary Medicine, Northwest Agriculture and For-
estry University. Every effort was made to minimize ani-
mal pain, suffering and distress and to reduce the number 
of animals used.
Serum‑virus neutralization test (SNT)
Sera collected at 0, 7, 14, 21 and 28 dpi were tested for 
neutralizing antibodies as previously described [19]. 
Briefly, serially diluted sera were mixed with an equal vol-
ume of 200  TCID50 of CSFV Shimen strain, incubated at 
37  °C for 1 h, added to PK-15 cells preplated in 96-well 
culture plates, and cultured for 3  days. The CSFV neu-
tralizing antibody (NAb) titers were determined and 
expressed as the reciprocal of the highest dilution at 
which infection of PK-15 cells was inhibited in 50% of the 
culture wells.
Statistical analysis
All experiments were performed with at least three 
independent experiments. Statistical significance was 
determined by the Student t test when two groups were 
compared, or by one-way analysis of variance (ANOVA), 
when more than two groups were compared. P 
value < 0.05 was considered to be statistically significant.
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Results
Identification of recombinant baculoviruses displaying 
complement interfering factors
Recombinant BV-VSVG-ED-pFc, BV-VSVG-ED-SPICE, 
BV-VSVG-ED-DAF and BV-VSVG-ED-OmCI baculo-
viruses were constructed by cloning pFc, SPICE, DAF 
or OmCI containing a N-terminal  His6 and C-terminal 
VSV-G (Figure 1A). The gp64 signal peptide was aimed at 
translocating the protein to the insect cell plasma mem-
brane and was cleaved, thus exposing the  His6 tag to the 
outer surface. To determine whether the complement 
interfering factors were properly translocated to the cell 
surface, the baculovirus-infected cells were collected at 
2 days after infection, and subjected to IFA. As shown in 
Figure  1B, the test proteins localized within the plasma 
membrane, demonstrating that the complement interfer-
ing factors were located on the surface of Sf-9 cells. To 
confirm the expression of  His6-tagged pFc, SPICE, DAF, 
and OmCI, Sf-9 cells were infected with recombinant 
BV-VSVG-ED-pFc, BV-VSVG-ED-SPICE, BV-VSVG-ED-
DAF and BV-VSVG-ED-OmCI baculoviruses, respectively, 
harvested at 3 days after infection, and used for detection. 
Western blot analyses showed that the complement inter-
fering factors were correctly expressed (Figure 1C).
Enhanced complement antagonism and transformation 
efficiency of recombinant baculoviruses
For application in vivo, recombinant baculoviruses should 
remain active in the presence of mammal sera. The sur-
vival rates of recombinant baculovirus vector were 
evaluated for complement antagonism. Recombinant 
BV-VSVG-ED-pFc, BV-VSVG-ED-SPICE, BV-VSVG-
ED-DAF, and BV-VSVG-ED-OmCI baculoviruses were 
treated and titrated as described above. In mouse serum, 
recombinant baculovirus display of DAF showed a higher 
complement antagonism activity (90.2%) than recombi-
nant baculovirus display of swine IgG1 Fc (pFc) (65.6%, 
P  <  0.05) (Figure  2A). As shown in Figure  2B, in pig 
serum, recombinant baculovirus display of pFc showed 
a significantly higher complement antagonism activity 
(75.6%, P  <  0.05) than other recombinant baculoviruses. 
Furthermore, BV-VSVG-ED demonstrated a higher com-
plement antagonism activity (P  <  0.05) compared with 
wild type BV-gp64. DsRed expression was analyzed by 
fluorescence microscopy following transduction of IEC 
cells with BV-VSVG-ED-pFc or BV-VSVG-ED at an MOI 
of 100 (Figures  3A and 3B). Transduction efficiency was 
further quantified by flow cytometry analysis, in which 
BV-VSVG-ED-pFc demonstrated significantly increased 
numbers of DsRed positive cells (Figure  3C), and the 
mean fluorescence intensity (MFI) of DsRed fluorescence 
was significantly higher with BV-VSVG-ED-pFc than with 
BV-VSVG-ED (Figure 3D). 
In vitro evaluation of BacMam expressing E2 based 
on swine IgG1 Fc surface display
Recombinant BV-VSVG-ED-CMV-E2 and BV-VSVG-
ED-pFc-CMV-S/P-E2 baculoviruses were constructed 
by replacing dsRed with CSFV E2 gene, and incorpo-
rating translational enhancers Syn21 and P10UTR to 
improve E2 expression (Figure  4A). Sf-9 cells infected 
with recombinant BV-VSVG-ED-CMV-E2 and BV- 
Figure 2 Evaluation of complement antagonism of recombinant baculoviruses displaying complement interfering factors in serum. 
A Baculovirus was incubated with 40% mice serum, and then subjected to titration by end-point dilution assays. Bars denote the percentage of vec-
tor survival, which was determined as the percentage of virus titer resulting from pre-incubation with untreated compared to heat-treated serum. 
Bars with different letters were significantly different (P < 0.05). B Baculovirus vector survival in pig serum tested as above. Bars with different letters 
were significantly different (P < 0.05).
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VSVG-ED-pFc-CMV-S/P-E2 baculoviruses were sub-
ject to Western blot analyses (Figure 4B), and it revealed 
that the E2 and  His6-tagged pFc protein were correctly 
expressed in Sf-9 cells. The results from IFA indicated that 
IEC cells transduced with BV-VSVG-ED-CMV-E2 and 
BV-VSVG-ED-pFc-CMV-S/P-E2 developed immunofluo-
rescence signals, confirming the expression of E2 protein 
in IEC cells. Particularly, BV-VSVG-ED-pFc-CMV-S/P-E2 
had higher efficiency of gene transduction compared with 
BV-VSVG-ED-CMV-E2 (Figure  4C). These data were in 
agreement with the complement antagonism result of 
BV-VSVG-ED-CMV-E2 and BV-VSVG-ED-pFc-CMV-
S/P-E2, which showed that BV-VSVG-ED-pFc-CMV-S/P-
E2 resulted in a significantly higher survival rate than that 
of BV-VSVG-ED-CMV-E2 (Figure 5) (P < 0.05).
Immune responses elicited by BV‑VSVG‑ED‑pFc‑CMV‑S/
P‑E2 in pigs
To explore the ability of BV-VSVG-ED-pFc-CMV-
S/P-E2 to induce CSFV-specific humoral immune 
responses, pigs were immunized with this baculovirus, 
as well as BV-VSVG-ED-CMV-E2, commercial vaccine 
C-strain, and PBS controls, and detected for E2-spe-
cific antibodies by ELISA. All the pigs immunized with 
BV-VSVG-ED-pFc-CMV-S/P-E2, C-strain vaccine, and 
BV-VSVG-ED-CMV-E2 developed high levels of anti-
body, without significant difference. The pigs immunized 
with PBS only demonstrated a non-specific antibody 
response below the threshold (Figure 6A).
To detect CSFV-specific NAb titers, SNT was performed 
at 0, 7, 14, 21 and 28 dpi. The results showed that pigs 
immunized with the commercial vaccine C-strain devel-
oped the highest NAb titers, and those immunized with 
BV-VSVG-ED-pFc-CMV-S/P-E2 also induced considerable 
level of Nabs, followed by those immunized with BV-VSVG-
ED-CMV-E2. Nevertheless, the pigs immunized with PBS 
did not develop a detectable NAb titer against CSFV even at 
4 weeks following prime immunization (Table 1).
The IFN-γ levels in immunized sera can reflect the 
immune state of the host. IFN-γ secreted by T-helper 
Figure 3 Surface displayed swine IgG1 Fc enhanced baculovirus-mediated DsRed expression. A, B Fluorescent microscopic analysis of 
transduced IEC cells 36 h after transduction (×100). C, D Flow cytometry analysis of transduced cells. C Percentage of DsRed positive cells in IEC. D 
Mean fluorescence intensity (MFI) of DsRed positive IEC cells (**P < 0.05).
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type 1 (Th1) cells plays important roles in regulating the 
cellular immune response. The serum IFN-γ concentra-
tions (14 and 28 dpi) were a little higher in the group 
immunized with commercial vaccine C strain than the 
group immunized with BV-VSVG-ED-pFc-CMV-S/P-
E2, but not significantly different. Most notably, the 
IFN-γ level in the group immunized with BV-VSVG-
ED-pFc-CMV-S/P-E2 was significantly higher than that 
of the group immunized with BV-VSVG-ED-CMV-E2 
(P < 0.05) (Figure 6B) (P < 0.05).
Discussion
Baculoviruses are insect-specific viruses in nature, thus 
being non-pathogenic for mammals. Baculovirus has 
been proved to be able to transduce various mammalian 
cells of human, rodent, porcine, canine, avian, feline and 
rabbit origins. BacMam viruses are emerging as a gene 
delivery vector with additional advantages over conven-
tional vectors.
In this study, considering the complement-mediated 
inactivation of baculovirus, we developed four baculovi-
rus constructs displaying complement interfering factors, 
and by in  vitro evaluation of complement antagonism, 
the baculovirus displaying pFc achieved a survival rate up 
to 75.6% in pig serum and 65.6% in mouse serum. Flow 
cytometry analysis of transduced IEC cells, a cell line 
with high level expression of Fc receptors, demonstrated 
that the baculovirus display of pFc showed a significant 
increase in transduction efficiency (57.5 vs 16.7%) and 
transgene expression of reporter genes. These results 
revealed that baculovirus displaying pFc can be used as a 
promising vaccine delivery vector.
To test the potential of baculovirus displaying pFc as a 
vaccine delivery vector in vivo, a novel baculovirus vac-
cine for CSFV was constructed. In terms of optimizing 
the vaccine constructs, the regulatory elements VSV-G 
increased antigen presentation, and Syn21 and P10UTR 
improved antigen expression. Although it did not develop 
Figure 4 Characterization and evaluation of BacMam expressing E2 based on swine IgG1 Fc surface display. A Schematic diagram 
of donor vectors of BacMam virus vaccines. B Western blot detection of pFc and E2 protein expression in insect cells infected with recombinant 
baculoviruses. BV-VSVG-ED-CMV-E2 or BV-VSVG-ED-pFc-CMV-S/P-E2-infected Sf-9 cells were harvested 2 days after infection and used for analysis. 
The E2 protein (55 kDa) was detected by rabbit anti-CSFV polyclonal antibody, and  His6-tagged pFc (27 kDa) was analyzed by anti-His6 monoclonal 
antibody. Anti-β-actin was included as an internal control. C IFA detection of expression of E2 protein in BV-VSV-ED-CMV-E2 or BV-VSVG-ED-pFc-
CMV-S/P-E2-transduced IEC cells. The cells were fixed at 48 h after transduction, and analyzed by rabbit anti-CSFV polyclonal antibody and Alexa 
594-conjugated goat anti-rabbit IgG. Uninfected IEC cells were served as a negative control.
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comparative immune response as the commercial vac-
cine C-strain, this baculovirus vaccine demonstrated a 
potential for further usage. The high titers of CSFV-spe-
cific antibody and neutralizing antibody, and increased 
levels of IFN-γ secretion indicated that the baculovirus 
effectively delivered exogenous antigen to the swine cells 
and stimulated the production of humoral and cellular 
immune responses. These results suggest a promising 
vaccine strategy based on the BacMam virus and baculo-
virus surface display system. It is notable that BV-VSVG-
ED-pFc-CMV-S/P-E2 induced stronger CSFV-specific 
immune response than BV-VSVG-ED-CMV-E2, poten-
tially because it has the translational enhancers Syn21 
and P10UTR.
Another important question needing to be addressed 
is that surface display system-based IgG1 Fc makes a 
great difference in the efficacy of the BV-VSVG-ED-
pFc-CMV-S/P-E2 vaccine. IgG Fc has been intensely 
investigated as a scaffold for the design of novel thera-
peutics due to its beneficial biological and pharma-
cological properties. One of the benefits of Fc-fusion 
proteins is their interaction with the neonatal Fc recep-
tor (FcRn) on immune cells, thus to increase plasma 
half-life, and prolong therapeutic activity, providing a 
new perspective for vaccine development [20, 21]. It has 
been demonstrated that the Fc part of IgG or IgY (egg 
yolk antibody) can function as an immunoenhancer 
[22, 23]. The Fc can also fold in its independent manner 
and facilitate the stability of the fused proteins. In most 
cases, the Fc domain forms homodimers with higher 
affinity for the FcγRs, which enhances binding and the 
signaling capacity. Takashima et  al. demonstrated that 
pseudorabies virus surface displaying IgG1 Fc gives 
rise to a better immune efficacy [24]. They also found 
that vaccination with recombinant cell surface express-
ing mouse IgG Fc achieves an increase in interleukin, 
but does not activate the complement classical pathway 
[25]. Another group has proved that surface display of 
IgG Fc on baculovirus vectors could enhance the bind-
ing to antigen-presenting cells and cell lines expressing 
Fc receptors [26]. These findings indicate that bacu-
lovirus based on IgG Fc surface display can be further 
explored as a vaccine strategy.
Our study demonstrates that the surface displayed Fc 
markedly improved the potency of BacMam virus. The 
molecular mechanism underlying this enhanced efficacy 
may include the following: (1) prolonging baculovirus-
vectored vaccine half-life and promoting effective antigen 
presentation by interaction with FcRn, (2) using adjuvant 
function of IgG antibody Fc to activate stronger innate 
and adaptive immunity by interaction with FcγRs, usu-
ally with high level expression in immune cells (dendritic 
cells, macrophage, and B cells), thus enhancing the sign-
aling capacity for the immune system, and (3) escaping 
from complement-mediated inactivation in the similar 
way of Fc-fusion drugs and recombinant cells displaying 
IgG1 Fc [25, 27–29].
The in  vitro studies have proved that baculovirus can 
bind directly to IgM and C3b in serum, thus activating 
the classical and alternative pathways [30]. Our previ-
ous study has also demonstrated that the complement 
derived from pig serum inactivated baculovirus by acti-
vating the classical and alternative pathways (Additional 
file  1). Interestingly, we found that BV-VSVG-ED-pFc 
bound more poorly to IgM in pig serum compared to 
BV-VSVG-ED, indicating that this surface-displaying 
swine IgG1 Fc resulted in an increase in complement 
escape by the classical pathway (Additional file  2). To 
some extent, this phenomenon was in agreement with 
previous observations that most Fc-fusion drugs and 
recombinant cells displaying IgG1 Fc demonstrated 
remarkable complement antagonism, partially because 
Figure 5 Complement antagonism of BacMam vaccine vectors 
in pig serum. Baculovirus was incubated with 40% pig serum, and 
then subjected to titration by end-point dilution assay. Bars denote 
the percentage of vector survival, which was determined as the 
percentage of virus titer resulting from pre-incubation with untreated 
compared to heat-treated serum. There was significant difference 
between BV-VSVG-ED-pFc-CMV-S/P-E2 and BV-VSVG-ED-CMV-E2 
(**P < 0.05).
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complement activation depends on the Fab (especially 
the CH1 domain) and hinge area [31].
In addition to serum complement, baculovirus-spe-
cific adaptive immunity also neutralizes the particles and 
impedes subsequent baculovirus injection in  vivo [32]. 
Given that the BV-VSVG-ED-pFc-CMV-S/P-E2 vaccine 
was initially tested to evaluate immune responses in pigs 
with an immune procedure without optimization, though 
the baculovirus vector surface-displaying pFc potentiated 
higher level of E2-specific antibody, CSFV neutralizing 
antibody titer, and IFN-γ than that without pFc surface 
display, the efficiency of adaptive immune responses was 
a little lower than the commercial vaccine C-strain. There-
fore, it can be improved for better efficacy by using a 
3-week immunization interval or adoption of heterologous 
prime-boost vaccine strategy. Heterologous prime-boost 
regimens mostly use a viral or DNA vector for priming, 
followed by a boost with a subunit vaccine. This immu-
nization strategy combines a stronger cellular immune 
response with a higher antibody response against the vac-
cine target compared to homologous immunization and 
can overcome the issue of anti-vector immunity [33].
We aimed to break the bottlenecks limiting baculovi-
rus-based gene delivery for mammals. The swine IgG1 Fc 
displayed on the BV-VSVG-ED-pFc-CMV-S/P-E2 surface 
was closely related to the transduction efficiency target-
ing cells harboring Fc receptors, IEC cells in this study, 
and it also facilitated baculovirus escape from the com-
plement in pig serum. A more comprehensive under-
standing of this BacMam based vaccine is essential to 
improve the immunogenicity of the baculovirus vector. 
To this end, we are currently focusing on two issues: (1) 
exploring in more detail the interaction between the bac-
ulovirus vector surface-displaying pFc and Fc receptors 
Figure 6 Detection of antibody and cellular immune responses induced by recombinant baculoviruses. A Antibody levels in sera of 
immunized pigs by indirect ELISA. Four groups of pigs were intramuscularly injected twice with commercial vaccine C-strain, BV-VSVG-ED-pFc-CMV-
S/P-E2 or BV-VSVG-ED-CMV-E2 at a 1-week interval. Serum samples from each group were collected weekly and tested. A dashed line indicates the 
positive cutoff value of ELISA (OD630 nm = 0.35). B IFN-γ levels in sera of immunized pigs by ELISA. Serum samples from each group were collected 
and tested using a commercial ELISA kit (4A Biotech, Beijing, China) for quantitative detection of pig IFN-γ. Bars with different letters were signifi-
cantly different (P < 0.05).
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or elements in the pig serum complement system and 
(2) testing BV-VSVG-ED-pFc-CMV-S/P-E2 in differ-
ent immunization schedules to induce stronger immune 
responses.
In summary, this study provides supporting evidence 
for the use of the BacMam virus as a vaccine delivery vec-
tor. This novel VSV-G-pseudotyped baculovirus based on 
IgG1 Fc surface display offers an alternative strategy for 
vaccine development for CSFV and other pathogens.
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Table 1 CSFV-specific neutralizing antibody titers in pigs immunized with BV-VSVG-ED-pFc-CMV-S/P-E2 at different days 
post-immunization
Four groups (n = 5) of 4 week old pigs were immunized with BV-VSVG-ED-pFc-CMV-S/P-E2. Serum were collected at different time after the immunization, and 
subjected to detection of CSFV-specific neutralizing antibodies (NAbs) by serum-virus neutralization test (SNT). X  ± S: mean ± standard deviation. Group A-D indicate 
pigs immunized with PBS, CSFV commercial vaccine C-strain, BV-VSVG-ED-CMV-E2 and BV-VSVG-ED-pFc-CMV-S/P-E2, respectively.
Groups Pig No. Days post‑immunization
0 7 14 21 28
NAbs
A 039 <1 <1 <1 <1 <1
075 <1 <1 <1 <1 <1
086 <1 <1 <1 <1 <1
116 <1 <1 <1 <1 <1
200 <1 <1 <1 <1 <1
X  ± S <1 <1 <1 <1 <1
B 022 <1 6 16 64 128
046 <1 8 16 64 128
105 <1 6 16 64 128
142 <1 8 24 80 144
183 <1 8 16 64 108
X  ± S <1 7.2 ± 1.1 17.6 ± 3.6 67.2 ± 7.2 131.5 ± 12.8
C 035 <1 6 8 16 44
056 <1 8 8 16 64
073 <1 6 8 32 64
117 <1 8 12 16 64
152 <1 4 8 16 64
X  ± S <1 6.4 ± 1.7 8.8 ± 1.8 19.2 ± 7.2 60 ± 8.9
D 026 <1 6 12 48 84
084 <1 8 16 48 96
093 <1 6 12 64 96
128 <1 8 16 48 100
192 <1 4 16 64 88
X  ± S <1 6.4 ± 1.7 14.4 ± 2.2 54.4 ± 8.8 95.2 ± 6.6
Additional files
Additional file 1. Effect of chelating agents on the survival of 
baculovirus in pig serum. Baculovirus vectors were pre-incubated with 
90% serum for 60 min at 37 °C with or without the addition of a chelating 
agent, 20 mM EDTA, to chelate  Ca2+and  Mg2+, thereby inhibiting all 
three complement pathways, or 20 mM EGTA/14 mM  MgCl2 to chelate 
 Ca2+, thereby isolating the alternative pathway. The survival of virus was 
determined by point-end dilution assay on Sf-9 insect cells. Bars denote 
the percentage of vector survival in the indicated sera referred to the cor-
responding heat-treated sera. Data represent mean ± standard deviation 
(SD) of three experiments each of two repeats. Survival in EDTA serum was 
significantly improved compared with normal serum (P < 0.05).
Additional file 2. Detection of interaction between IgM in pig 
serum and recombinant baculoviruses by ELISA. 7 × 106 pfu of 
baculovirus was coated, and then exposed to pig serum, followed by 
addition of HRP-conjugated goat-anti-swine IgM. Bars denote the  OD450. 
The assay was performed in triplicate and the data are presented as mean 
± SD (**P < 0.05).
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